Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Coramitug PET/CT imaging study in ATTR amyloidosis cardiomyopathy
NL-OMON58839Phase 1Recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, single-arm trial of coramitug in amyloidotic transthyretin cardiomyopathy (ATTR-CM), sponsored by Novo Nordisk. Started Feb 2026; status: recruiting.
02
Drugs
coramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NL-OMON58839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58839.